This is a randomized, dose-ranging efficacy trial of oral dideoxyinosine in zidovudine-intolerant HIV infected patients with AIDS or ARC and CD4 counts of 300 mm3 or less, or asymptomatic infection with CD4 counts of 200 mm3 or less.
Showing the most recent 10 out of 426 publications